$2.46
-0.04 (-1.60%)
Open$2.50
Previous Close$2.50
Day High$2.52
Day Low$2.46
52W High$3.61
52W Low$2.09
Volume—
Avg Volume24.4K
Market Cap76.22M
P/E Ratio—
EPS$-1.49
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+386.6% upside
Current
$2.46
$2.46
Target
$11.97
$11.97
$8.96
$11.97 avg
$15.34
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 51.54M | 48.92M | 53.08M |
| Net Income | -6,374,638 | -6,659,114 | -5,888,081 |
| Profit Margin | -12.4% | -13.6% | -11.1% |
| EBITDA | -7,191,271 | -7,364,625 | -7,497,793 |
| Free Cash Flow | -8,326,283 | -5,338,476 | -7,416,749 |
| Rev Growth | +3.4% | -7.2% | +0.9% |
| Debt/Equity | 0.61 | 0.70 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |